Article

New OAB therapies are on the way

With seven approved drugs for overactive bladder already on the market, the potential for new treatments might seem to be limited. The reality is that OAB treatment is still not optimal.

Related Videos
1 expert is featured in this series.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Wayne Kuang, MD, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
FDA clears chemiluminescence-based immunoassay for free testosterone
January 10th 2025

FDA clears chemiluminescence-based immunoassay for free testosterone

Hannah Clarke
The test can provide results in 48 minutes to provide diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC
January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke
"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC
January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke
Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.
Disitamab vedotin/toripalimab shows encouraging efficacy in urothelial carcinoma
January 8th 2025

Disitamab vedotin/toripalimab shows encouraging efficacy in urothelial carcinoma

Hannah Clarke
At a median follow-up of 33.2 months, the confirmed objective response rate was 73.2%.
© 2025 MJH Life Sciences

All rights reserved.